MPN

From Philadelphia Flyers’ employees suing the organization after developing a rare blood cancer to experts proposing a new name for low-risk prostate cancer and an actor on Disney+’s “The Mandolorian” dying of cancer, here’s what is happening in the cancer space this week.

Patients with myeloproliferative neoplasms, a group of blood cancers, who plan to conceive should talk with their doctor about their obstetric and medical history and risk of complications, according to an expert.

A patient’s experience with polycythemia vera — a rare blood cancer — led to her becoming an advocate for others to help ease all the nerves and uncertainty that many patients face when they hear they have cancer.

Recently approved, by the Food and Drug Administration, Besremi has demonstrated to be effective and safe for patients with polycythemia vera — adding hope to their treatment regimen.

The Food and Drug Administration’s greenlight of Vonjo marks the first approved therapy to address the needs of patients with cytopenic myelofibrosis, a type of myeloproliferative neoplasm.

On behalf of the Canadian MPN Research Foundation, CURE spoke with Dr. Pierre Villeneuve, from the University of Ottawa, about the long-term care of MPNs.

On behalf of the Canadian MPN Research Foundation, CURE spoke with Dr. Pierre Villeneuve, from the University of Ottawa, about MPN resources and support groups available to patients and loved ones.

On behalf of the Canadian MPN Research Foundation, CURE spoke with Dr. Shireen Sirhan, from the Jewish General Hospital-McGIll University, about patients being their own best advocate in their MPN care.

On behalf of the Canadian MPN Research Foundation, CURE spoke with Dr. Shireen Sirhan, from the Jewish General Hospital-McGIll University, about finding a care team that specializes in MPNs.

On behalf of the Canadian MPN Research Foundation, CURE spoke with Dr. Pierre Villeneuve, from the University of Ottawa, about the role of caregivers after an MPN diagnosis.

Patients with cancer who receive bone marrow or stem cells from either a related or unrelated donor may experience similar outcomes and quality of life post transplant, which may highlight the efforts made by teams to help patients along the way.

A blood cancer specialist discusses how the development of tyrosine kinase inhibitors in the 1990s to treat chronic myelogenous leukemia drove major oncology advancements over the next three decades.

For patients with myelofibrosis, previously treated with Jakafi, momelotinib could be a major drug approval coming up, according to an expert.

When storytelling becomes a part of one’s identity, it can benefit a wide group of people — such as the MPN community — to share a potentially lifesaving message, according to LeVar Burton.

On this episode of the “Cancer Horizons” podcast, LeVar Burton sits down with CURE® to talk about the importance of MPN awareness and the power of storytelling in advocacy.

LeVar Burton, most noted for his roles in “Reading Rainbow” and “Star Trek”, stresses how important storytelling is — both in everyday life and in health care settings.

The Food and Drug Administration granted approval to Besremi for the treatment of adults with polycythemia vera.

Patients should understand the different prognostic scoring systems used in myelofibrosis, and how the results can impact treatment decisions.

Women with a myeloproliferative neoplasm can have healthy pregnancies, as long as they coordinate their care and know what to look out for.

Dr. Gabriela Hobbs offers insight into a rare cancer, myeloproliferative neoplasms, to help patients learn more during their treatment journey.

Keeping track of labs can help patients with MPN better understand the side effects and reasons for treatment , according to an expert from the Medical College of Wisconsin.

Patients who are living with MPN should live a healthy lifestyle and not compare their disease to others, because of variability between mutations, according to an expert.

Sierra Oncology completed enrollment for its phase 3 MOMENTUM clinical trial for the treatment of patients with myelofibrosis.

An expert explains the treatment options and personal life impacts of an essential thrombocythemia diagnosis.